Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be an experimental combination of three components: HMCuS (likely a copper sulfide-based nanoparticle or material), platinum (likely a platinum-based chemotherapeutic agent or nanoparticle), and indocyanine green (ICG, a FDA-approved near-infrared fluorescent dye). Based on the search results, ICG is a tricarbocyanine molecule with fluorescent properties used in medical diagnostics and increasingly in surgical oncology applications. ICG has a molecular mass of 776 Daltons, binds to plasma proteins after intravenous injection, and is metabolized by the liver. It exhibits peak spectral absorption at approximately 800 nm and emission at 822 nm. The combination likely represents a theranostic (therapeutic and diagnostic) nanoplatform that may utilize ICG's fluorescence imaging capabilities for tumor visualization, platinum's cytotoxic properties for cancer treatment, and HMCuS's potential photothermal or photodynamic properties. However, specific information about this exact combination formulation is not available in the provided search results.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HMCuS + platinum + indocyanine green.